COVID-19 Chronicles: Bring Automation to Continuous Manufacturing in the Pharmaceutical Industry with Data Analytics-as-a-Service

Subscribe To Read This Insight

By Kateryna Dubrova | 3Q 2020 | IN-5877


Advancing Pharmaceutical Industry with Continuous Manufacturing


The year 2020 has become a year of economic instability, industrial restructuring, consumer uncertainty, and global pandemic. COVID-19 is impacting various industries, showcasing supply chains’ lack of resilience and agility and challenging the global overproduction and consumerism culture. Despite pressure and uncertainty, the pharmaceutical, healthcare, and technology industries are the most critical industries of the COVID-19 world. Having experienced substantial growth during COVID-19, the pharmaceutical industry is undergoing a transition toward automation and continuous manufacturing. The pandemic is accelerating standards, data-enabled decision making, and Machine Learning (ML)-driven drug discovery.

The pharmaceutical industry and the chemical production, biopharma, and bio-med domains are strongly interconnected with the Internet of Things (IoT), data-enabled technologies, and data-driven applications. Since the rapid digitalization and automation of the pharmaceutical industry, the volume and variety of data have grown dramatically, esp…

You must be a subscriber to view this ABI Insight.
To find out more about subscribing contact a representative about purchasing options.